|
Aus dem Quartalsreport: Anticipated Near-Term Clinical Milestones Clinical Trial Readouts: • Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017) • Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017) • Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018) Second Quarter 2017 Financial Results: Research and development (R&D) expenses: R&D expenses were $5.0 million for the quarter ended June 30, 2017 compared to $5.3 million for the comparable period in 2016. The decrease in R&D expenses was primarily due to a reduction in the costs of our previously initiated clinical trials which was partially offset by the initiation of our ADVANCE-1 study with AXS-05 and the conduct of the AXS-06 Phase 1 trial. General and administrative (G&A) expenses: G&A expenses were $1.7 million for the quarter ended June 30, 2017 compared to $1.5 million for the comparable period in 2016. The increase in G&A expenses was primarily due to higher intellectual property and stock compensation expenses. Net loss: Net loss was $7.1 million, or $(0.30) per share, for the quarter ended June 30, 2017 compared to a net loss of $6.8 million, or $(0.36) per share, for the quarter ended June 30, 2016. Cash: As of June 30, 2017, Axsome had $38.0 million of cash compared to $36.6 million of cash as of December 31, 2016. Shares outstanding: As of June 30, 2017, Axsome had 23,608,084 shares of common stock outstanding. Financial guidance: Axsome believes that its cash as of June 30, 2017 will be sufficient to fund the company’s anticipated operations, based on its current operating plans, into the first quarter of 2019. |
|
| aus der Diskussion: | AXSM (Mkap $83 M) (Cash $40 M) 4 x Phase 3 Studien /erste Daten im 2H 2017 |
| Autor (Datum des Eintrages): | wandstrasse-ch (09.08.17 15:17:27) |
| Beitrag: | 121 von 268 (ID:55489287) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |